

CTAG2 Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP13767c**Specification**

CTAG2 Antibody (Center) Blocking peptide - Product Information

Primary Accession [O75638](#)

CTAG2 Antibody (Center) Blocking peptide - Additional Information

Gene ID 30848

Other Names

Cancer/testis antigen 2, CT2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 62, CT62, L antigen family member 1, LAGE-1, CTAG2, ESO2, LAGE1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13767c was selected from the Center region of CTAG2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CTAG2 Antibody (Center) Blocking peptide - Protein Information

Name CTAG2

Synonyms ESO2, LAGE1

Tissue Location

Testis and very low level in placenta and in some uterus samples. Observed in 25-50% of tumor samples of melanomas, non- small-cell lung carcinomas, bladder, prostate and head and neck cancers

CTAG2 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CTAG2 Antibody (Center) Blocking peptide - Images

CTAG2 Antibody (Center) Blocking peptide - Background

This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID 10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternative splicing results in multiple transcript variants. [provided by RefSeq].

CTAG2 Antibody (Center) Blocking peptide - References

Wang, X.Y., et al. Oncol. Rep. 21(3):713-719(2009) Shao, Y., et al. J. Cancer Res. Clin. Oncol. 134(4):495-502(2008) Andrade, V.C., et al. Cancer Immun. 8, 2 (2008) : Kan, T., et al. Oncology 70(1):25-33(2006) Scanlan, M.J., et al. Immunol. Rev. 188, 22-32 (2002) :